AMES, IA – February 26, 2014 - NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, today announced the appointment of Eugene P. Kennedy, M.D., FACS, as Vice President for Clinical and Medical Affairs. Dr. Kennedy will be responsible for clinical operations related to NewLink's HyperAcute® and IDO (indoleamine-(2,3)-dioxygenase) pathway product candidates as well as supporting commercial development strategies. "We are delighted that Dr. Kennedy has joined our team," commented Nicholas Vahanian, M.D., Chief Medical Officer of NewLink. "I had the distinct pleasure of working with Gene during NewLink's Phase 2 pancreatic cancer trial with algenpantucel-L. He is a tremendously talented physician and we look forward to his many contributions to NewLink in the future. Gene's appointment aligns with our expanded clinical and commercial activities as NewLink's HyperAcute and IDO programs continue to advance in development."
Dr. Kennedy comes to NewLink from Thomas Jefferson University in Philadelphia, PA where he served as Associate Professor of Surgery and held leadership positions as Chief of the Section of Pancreaticobiliary Surgery and Co-Director of the Jefferson Pancreas, Biliary, and Related Cancers Center. Previously, Dr. Kennedy has held faculty positions at the Johns Hopkins Hospital in Baltimore, MD and the Louisiana State University School of Medicine in New Orleans, LA. He has considerable experience in clinical trial design and implementation, leading both investigator initiated and industry sponsored efforts. Dr. Kennedy obtained his undergraduate education at the University of Virginia and received his medical degree from the Medical College of Virginia. He completed a residency and fellowship in Surgery and Surgical Oncology as well as a research fellowship in tumor immunology at the Johns Hopkins Hospital.
About NewLink Genetics Corporation
NewLink is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve treatment options for patients with cancer. NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink's product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens. For more information please visit http://www.linkp.com.
Investor Contact:Gordon LinkChief Financial Officer515email@example.comMedia Contact:Gina NugentThe Yates Networkgina@theyatesnetwork.com
SOURCE: NewLink Genetics Corporation